Additional file 7: of A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

Immunoglobulin levels following LCAR-B38M infusion. Levels of serum IgA, IgG, lambda chain, and kappa chain following CAR T cell infusion. (DOCX 281Â kb)